Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Lawsuit Eligibility

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of General Health and Science Information

For decades, the Immunodeficiency Foundation has served as a trusted repository for general health and science information, chronicling the broad evolution of medical understanding. Its archives have documented foundational principles of immunology, public health milestones, and the gradual refinement of therapeutic approaches across numerous conditions. This legacy of comprehensive, neutral scholarship provides essential context for examining how certain treatments intersect with patient safety in real-world settings. Within this broad landscape, one area of increasing focus involves the long-term implications of biologic therapies. Specifically, medications designed to modulate immune function—such as Tysabri—have been associated with heightened vulnerability to opportunistic infections. Among these, Progressive Multifocal Leukoencephalopathy (PML) represents a serious concern that has prompted extensive clinical monitoring and, in some cases, legal scrutiny.

Transition from General Education to Legal Inquiry

The transition from general health education to occupational exposure concern arises naturally when considering the responsibilities of healthcare providers and manufacturers. Patients and families affected by PML following Tysabri use may seek legal recourse, raising questions about informed consent, risk disclosure, and product liability. This pivot from archival knowledge to actionable legal inquiry underscores the practical importance of maintaining rigorous scientific records. The Foundation’s historical documentation thus serves not only as an academic resource but also as a foundation for understanding contemporary litigation surrounding Tysabri exposure and PML risk.

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. The condition is caused by the JC virus, which reactivates under conditions of immune suppression. Clinically, PML presents with a range of neurological deficits that evolve over weeks to months. Common symptoms include progressive weakness on one side of the body, cognitive decline, visual disturbances (such as hemianopia), ataxia, and speech difficulties. Diagnosis is confirmed through brain MRI, which typically shows multifocal, asymmetric white matter lesions without mass effect, and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). In some cases, brain biopsy may be necessary. The prognosis is poor: PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Tysabri Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to the alpha-4 subunit of integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This mechanism reduces inflammatory activity in MS and CD but also impairs immune surveillance in the brain. The drug is administered as an intravenous infusion every four weeks. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1,869 MS patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1,043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other common adverse reactions include headache, influenza-like illness, peripheral edema, and infections such as sinusitis and urinary tract infections.

Mechanistic Pathways Linking Tysabri to PML

The development of PML in Tysabri-treated patients is linked to the drug's mechanism of action. By blocking the adhesion molecule VLA-4 on lymphocytes, Tysabri prevents these cells from entering the brain parenchyma. This reduces the normal immune surveillance that controls JCV replication. In the absence of adequate T-cell monitoring, JCV can reactivate and infect oligodendrocytes, leading to demyelination and the characteristic lesions of PML. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies (indicating prior JCV exposure), longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy.

Adequacy of Warnings Regarding Tysabri and PML

The prescribing information for Tysabri includes a boxed warning that clearly states the drug increases the risk of PML, an opportunistic viral infection that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also identifies the three risk factors and advises that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML. Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML. Because of the risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which aims to ensure that patients are informed of the risks and that monitoring is performed. Despite these warnings, questions may arise about whether the risks were adequately communicated to patients and whether monitoring protocols were followed appropriately.

Attorney-Related Considerations for Affected Patients

Patients who have developed PML after receiving Tysabri may be eligible to pursue legal action. Key considerations include whether the prescribing physician adequately warned the patient about the risk of PML, whether the patient's risk factors (such as anti-JCV antibody status or prior immunosuppressant use) were properly assessed, and whether monitoring for early symptoms was conducted. The timeline between exposure and documented harm is critical: PML typically occurs after prolonged treatment, often beyond two years, but cases have been reported after as few as eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients should consult with an attorney experienced in pharmaceutical litigation to evaluate the specifics of their case, including medical records, prescribing history, and the timing of symptom onset. Legal claims may involve allegations of failure to warn, negligence, or product liability.

Timeline Between Exposure and Documented Harm

The onset of PML in Tysabri-treated patients is variable. In clinical trials, the two MS patients developed PML after a median treatment duration of 120 weeks (approximately 2.3 years), while the Crohn's disease patient developed PML after eight doses (approximately 8 months) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Post-marketing data indicate that the risk increases with longer treatment duration, especially beyond two years. Early detection is crucial: withholding Tysabri at the first sign or symptom suggestive of PML may improve outcomes. However, once PML is established, the prognosis remains poor, with most patients experiencing severe disability or death.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how does it increase the risk of PML?

Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It works by blocking immune cells from entering the brain, which reduces inflammation but also impairs immune surveillance, allowing the JC virus to reactivate and cause PML. The risk is higher in patients with anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms and diagnosis of PML?

PML symptoms include progressive weakness, cognitive decline, visual disturbances, ataxia, and speech difficulties. Diagnosis is confirmed by brain MRI showing white matter lesions and detection of JCV DNA in cerebrospinal fluid. Prognosis is poor, often leading to severe disability or death (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can patients affected by Tysabri-related PML file a lawsuit?

Yes, patients who developed PML after Tysabri use may be eligible to pursue legal action. Key factors include whether the risks were adequately communicated, whether risk factors were assessed, and whether monitoring was conducted. Consulting an attorney experienced in pharmaceutical litigation is recommended.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.